Blog Stats
- 84,171 hits
www.friedmanconsultingllc.com
Blogroll
Franck's Pharmacy
InfuPharma
IPA Canada Seminars
New England Compounding Center
TUNGSTEN SHIELD WEBINARS
Warning Letters
-
Recent Posts
- FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012
- APOTEX INC RECEIVES WARNING LETTER FOR MULTIPLE CANADIAN SITES (2/21/13) PART II
- APOTEX INC RECEIVES WARNING LETTER FOR MULTIPLE CANADIAN SITES (2/21/13)
- JUBILANT HOLLISTERSTIER RECEIVES WARNING LETTER (2/13/13)
- MEDI-FARE DRUG AND HOME HEALTH CENTER, BLACKSBURG, SC RECEIVES WARNING LETTER (3/7/13)
Archives
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
Categories
- 483
- Adverse Determination Letter
- Compounding Pharmacy
- Consent Decree
- Dietary Supplements
- FDA Compliance
- Import Alert
- Import Ban
- Microbiological Issues
- New Guidances for Industry
- Permanent Injunction
- Positron Emission Tomography (PET)
- Purpose and Scope
- Recall
- Regulatory Compliance
- Seizure
- Uncategorized
- Warning Letters
- Webinar
Pages
- 2013 UPCOMING WEBINAR/CONFERENCES/SEMINARS (UPDATED 02/28/13)
- ABOUT
- “HOT TOPICS” AVAILABLE FOR USP GENERAL CHAPTER PET 823
- Guidance – PET Drugs – cGMP (August 2011)
- MEDIA FILLS FOR VALIDATION OF ASEPTIC PREPARATIONS FOR POSITRON EMISSION TOMOGRAPHY(PET)
- Proposed Changes to USP General Chapter 823 March 30, 2011
- REGULATORY COMPLIANCE/EXPERT MICROBIOLOGICAL WITNESS CONSULTATION
- USP 61/62 FREQUENTLY ASKED QUESTIONS
Tags
Accugenix API Aseptic Processing Bacillus cereus bacterial contamination Ben Venue CDER CMO Consent Decree DNA Sequencing Environmental Monitoring FDA FDA 483 FDA Compliance FDA Guidance for Industry Growth Promotion H & P Industries Hospira interventions Johnson & Johnson McNeil-PPC media fills microbial contamination NECC Objectionable microorganisms Observations OOS PDI Permanent Injunction PET Puerto Rico purified water Ranbaxy Recall seizure sterile drug products Sterility Sterility Test training Triad Group USP USP 62 Validation Warning Letter Warning LettersMeta
Author Archives: Barry A. Friedman, PhD LLC
FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012
COMMENT Each year CDER summarizes the number of significant Observations obtained from Form FDA 483s. Enclosed are the “top fifteen” Observations. The Observations within the top fifteen usually do not change — although their frequency and ranking may vary. Please note … Continue reading
APOTEX INC RECEIVES WARNING LETTER FOR MULTIPLE CANADIAN SITES (2/21/13) PART II
FDA INVESTIGATOR FINDS INACCURATE REPORTING OF MICROBIOLOGICAL DATA The FDA, during August and October 2012 inspected two Apotex, Inc. sites. This Blog only discusses the facilities located at 150 Signet Drive, Toronto, Canada. The U.S. Food and Drug Administration (FDA) … Continue reading
APOTEX INC RECEIVES WARNING LETTER FOR MULTIPLE CANADIAN SITES (2/21/13)
FIRM FAILED TO ESTABLISH AND FOLLOW PROCEDURES DESIGNED TO PREVENT MICROBIOLOGICAL CONTAMINATION (21 CFR 211.113(b)) The FDA, during August and October 2012 inspected two Apotex, Inc. sites. This Blog only discusses the facilities located at 150 Signet Drive, Toronto, Canada. … Continue reading
JUBILANT HOLLISTERSTIER RECEIVES WARNING LETTER (2/13/13)
ASEPTIC FILLING FACILITY RECEIVES SIGNIFICANT OBSERVATIONS Jubilant HollisterStier located in Kirkland, Quebec, Canada was audited by the FDA on March 19-26, 2012. Following the receipt of the Form FDA 483, the Company responded on April 13, 2012 to the Observations … Continue reading
MEDI-FARE DRUG AND HOME HEALTH CENTER, BLACKSBURG, SC RECEIVES WARNING LETTER (3/7/13)
SERIOUS DEFICIENCIES ARE NOTED IN THE PRACTICE OF PRODUCING STERILE DRUGS BACKGROUND Recently the FDA has been criticized for its management of the New England Compounding Center. The following Warning Letter represents one of the first Warning Letters that the … Continue reading
CAPCO CUSTOM PACKAGING INC RECEIVES WARNING LETTER (02/20/13)
DIETARY SUPPLEMENT MANUFACTURING FACILITY FAILS TO ADEQUATELY PERFORM MICROBIOLOGICAL TESTING; FDA CITES INCORRECT USP CHAPTER COMMENTS Dietary Supplement Warning Letters have within the past several months been issued at a frequency of two to three each week. Many of these … Continue reading
ABBEY COLOR, PHILADELPHIA, PA RECEIVES WARNING LETTER (FEBRUARY 19, 2013)
API MANUFACTURING FACILITY IS CITED FOR SEVERAL REPEAT WATER RELATED OBSERVATIONS During the time frame of March 13 to March 23, 2012 the FDA inspected Abbey Color, an active pharmaceutical ingredient (API) manufacturing facility in Philadelphia, PA. Following a detailed … Continue reading
NOVO NORDISK A/S RECEIVES WARNING LETTER (Bagsvaerd, Denmark, 12/12/12)
LACK OF ENVIRONMENTAL MONITORING DURING 23 MONTHS ATTRACTS FDA ATTENTION Approximately one year ago (March 12 – 20, 2012), the FDA audited the Novo Nordisk A/S facility located at Novo Alle, Bagsvaerd, Denmark. During the audit the FDA encountered significant … Continue reading
HAMELN PHARMACEUTICALS, HAMELN, GERMANY RECEIVES WARNING LETTER (12/17/12)
IN-HOUSE STERILITY TESTING METHOD NOT EQUIVALENT TO USP<71> During the time frame of June 4 – 14, 2012, the Hameln facility was audited by the FDA. Following the audit, the firm responded on July 4, August 2 and 31, and … Continue reading
PERFORMANCE PRODUCTS INC, ST LOUIS, MO RECEIVES WARNING LETTER (11/20/12)
COMPANY FAILS TO REPLY TO FORM FDA 483 FROM JULY 2012 AUDIT Compliance Products, St. Louis, MO was audited by the Kansas City office of the FDA from July 16-20, 2012. Following the audit, a total of eight Observations were … Continue reading
